|Articles|June 2, 2019
- BioPharm International-06-15-2019
- Volume 2019 eBook
- Issue 2
Extractables and Leachables: Determining Risk in Single-Use Systems
Author(s)Andreas Nixdorf
As SUS become prevalent in the biologics industry, the question of safety becomes increasingly important.
Advertisement
Single-use systems (SUS) are increasingly becoming the norm in biologics development and manufacturing. Approximately 85% of the pre-commercial biopharmaceutical sector use SUS, and they are increasingly being adopted for commercial manufacturing. SUS have significant advantages but are not without drawbacks. A 2018 survey showed that 73.3% of biologics insiders listed contamination from extractables and leachables to be a major problem.
Read
Article Details
BioPharm International
eBook: Single-Use Systems 2019
Vol. 32
June 2019
Pages: 20–23
Citation
When referring to this article, please cite it as A. Nixdorf, "Extractables and Leachables: Determining Risk in Single-Use Systems," BioPharm International Single-Use Systems eBook (June 2019).
Articles in this issue
over 6 years ago
New Strategies for Managing Single-Use Componentsover 6 years ago
The Importance of Single-Use Components for Bioprocessingover 6 years ago
Buffers Benefit from Single-Use Systemsover 6 years ago
Thinking Flexibly in Biomanufacturingover 6 years ago
Single-Use Bioreactors Unwrap Commercial Manufacturing OptionsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
4
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
5
